A practical reference on growth hormone secretagogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-22 and is reviewed periodically as new material appears.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility class | Soluble in water and aqueous buffers | Solubility can depend on pH and salt form |
| Typical storage temperature | −20 °C or lower, desiccated | Protect from light and moisture |
| Typical analytical method | RP-HPLC with UV detection; LC-MS | Identity and purity assessment |
| Common salt form | Acetate salt | Frequently used in research supply |
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Treponema pallidum, formerly known as Spirochaeta pallida, is a microaerophilic, gram-negative, spirochaete bacterium with subspecies that cause the diseases syphilis, bejel (also known as endemic syphilis), and yaws. It is known to be transmitted only among humans and baboons. T. pallidum can enter the host through mucosal membranes or open lesions in the skin and is primarily spread through sexual contact. It is a helically coiled microorganism usually 6–15 μm long and 0.1–0.2 μm wide. T. pallidum's lack of both a tricarboxylic acid cycle and processes for oxidative phosphorylation results in minimal metabolic activity. As a chemoorganoheterotroph, Treponema pallidum is an obligate parasite that acquires its glucose carbon source from its host. Glucose can be used not only as a primary carbon source but also in glycolytic mechanisms to generate ATP needed to power the bacterium given its minimal genome. The treponemes have cytoplasmic and outer membranes. Using light microscopy, treponemes are visible only by using dark-field illumination. T. pallidum consists of three subspecies, T. p. pallidum, T. p. endemicum, and T. p. pertenue, each of which has a distinct related disorder. The ability of T. pallidum to avoid host immune defenses has allowed for stealth pathogenicity. The unique outer membrane structure and minimal expression of surface proteins of T. pallidum has made vaccine development difficult. Treponema pallidum can be treated with high efficacy by antibiotics that inhibit bacterial cell wall synthesis such as the beta-lactam antimicrobial penicillin-G.
== History == In 1910, British physicist J. J. Thomson observed a release of positive ions and neutral atoms from a solid surface induced by ion bombardment. Improved vacuum pump technology in the 1940s enabled the first prototype experiments on SIMS by Herzog and Viehböck in 1949, at the University of Vienna, Austria. In the mid-1950s, Honig constructed a SIMS instrument at RCA Laboratories in Princeton, New Jersey. Then in the early 1960s, two SIMS instruments were developed independently. One was an American project, led by Liebel and Herzog, which was sponsored by NASA at GCA Corp, Massachusetts, for analyzing Moon rocks, and the other was at the University of Paris-Sud in Orsay by R. Castaing for the PhD thesis of G. Slodzian. These first instruments were based on a magnetic double-focusing sector field mass spectrometer and used argon for the primary-beam ions. In the 1970s, K. Wittmaack and C. Magee developed SIMS instruments equipped with quadrupole mass analyzers. Around the same time, A. Benninghoven introduced the method of static SIMS, where the primary ion current density is so small that only a negligible fraction (typically 1%) of the first surface layer is necessary for surface analysis. Instruments of this type use pulsed primary ion sources and time-of-flight mass spectrometers and were developed by Benninghoven, Niehuis, and Steffens at the University of Münster, Germany and also by Charles Evans & Associates. The Castaing and Slodzian design was developed in the 1960s by the French company CAMECA S.A.S. and used in materials science and surface science.
The vapor-compression cycle is used in most household refrigerators as well as in many large commercial and industrial refrigeration systems. Figure 1 provides a schematic diagram of the components of a typical vapor-compression refrigeration system. The thermodynamics of the cycle can be analyzed on a diagram as shown in Figure 2. In this cycle, a circulating refrigerant such as a low boiling hydrocarbon or hydrofluorocarbons enters the compressor as a vapour. From point 1 to point 2, the vapor is compressed at constant entropy and exits the compressor as a vapor at a higher temperature, but still below the vapor pressure at that temperature. From point 2 to point 3 and on to point 4, the vapor travels through the condenser which cools the vapour until it starts condensing, and then condenses the vapor into a liquid by removing additional heat at constant pressure and temperature. Between points 4 and 5, the liquid refrigerant goes through the expansion valve (also called a throttle valve) where its pressure abruptly decreases, causing flash evaporation and auto-refrigeration of, typically, less than half of the liquid. That results in a mixture of liquid and vapour at a lower temperature and pressure as shown at point 5. The cold liquid-vapor mixture then travels through the evaporator coil or tubes and is completely vaporized by cooling the warm air (from the space being refrigerated) being blown by a fan across the evaporator coil or tubes. The resulting refrigerant vapour returns to the compressor inlet at point 1 to complete the thermodynamic cycle.
== Interactions == Monoamine oxidase inhibitors (MAOIs) taken with amphetamine may result in a hypertensive crisis if taken within two weeks after last use of an MAOI type drug. Inhibitors of enzymes that directly metabolize amphetamine (particularly CYP2D6 and FMO3) will prolong the elimination of amphetamine and increase drug effects. Serotonergic drugs (such as most antidepressants) co-administered with amphetamine increases the risk of serotonin syndrome. Stimulants and antidepressants (sedatives and depressants) may increase (decrease) the drug effects of amphetamine, and vice versa. Gastrointestinal and urinary pH affect the absorption and elimination of amphetamine, respectively. Gastrointestinal alkalinizing agents increase the absorption of amphetamine. Urinary alkalinizing agents increase the concentration of non-ionized species, decreasing urinary excretion. Proton-pump inhibitors (PPIs) modify the absorption of Adderall XR and Mydayis. Zinc supplementation may reduce the minimum effective dose of amphetamine when it is used for the treatment of ADHD. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans.
Sources: en.wikipedia.org
Rejuva is a gene therapy which is under development for the treatment of obesity and diabetes. It is an adeno-associated virus (AAV)-based gene therapy which involves an engineered variant of human insulin promotor and which aims to permanently increase nutrient-responsive secretion glucagon-like peptide-1 (GLP-1) by pancreatic β-cells. The therapy is administered via a 25-gauge needle delivery system guided by endoscopic ultrasound in a one-time outpatient treatment. It is intended as a permanent alternative to GLP-1 agonists like semaglutide. Rejuva is under development by Fractyl Health and is in the preclinical research stage of development.
These multidisciplinary teams leverage the Barshop Institute's nationally recognized aging research programs—including the Nathan Shock Center of Excellence in the Basic Biology of Aging, the Claude D. Pepper Older Americans Independence Center, the Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies (CAPAS), and the Interventions Testing Program—to rapidly translate mechanistic discoveries into human studies. This integrated research environment enables investigators to evaluate interventions targeting the fundamental biological mechanisms of aging rather than focusing solely on individual diseases, reflecting the principles of geroscience that underpin the Institute's research mission. A landmark addition to the Institute's clinical research portfolio is the Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H) clinical trial, supported by a contract of up to $38 million from the Advanced Research Projects Agency for Health (ARPA-H) through its Proactive Solutions for Prolonging Resilience (PROSPR) program. As the coordinating center for this first-of-its-kind national healthspan clinical trial, the Barshop Institute is leading an unprecedented effort to determine whether FDA-approved medications can slow the biological processes of aging and preserve health and functional capacity before the onset of chronic disease.
=== Gel permeation chromatography === The research that appeared to spark an onslaught of modified applications was a gel permeation chromatography technique of fixing poly(isopropyl acrylate) (PIPA) strands to glass beads and separating a mixture of dextrans, which was developed by Gewehr et al. They found that between the temperatures of 25–32 °C, the elution time of dextrans at different molecular weights exhibited a dependence on the temperature. Dextrans of the highest molecular weight eluted first since the PIPA chains exhibit hydrophilicity at temperatures below the LCST. As the temperature of the elution increased, when the chains behave in a more hydrophobic manner, the elution times increased for each of the analytes for the given range. The trend generally applies over the entire temperature range, but there is a flattening of the curve before 25 °C and after 32 °C (the approximate LCST for this experiment). Above the LCST, the PIPA acts as a typical nonpolar stationary phase that would be used in reverse-phased chromatography. There are also instances of the elution times increasing below 15 °C, which most likely can be attributed to the lower temperatures’ effects on mass transfer playing a more significant role on retention than the stationary phase behavior. This study showed that the resolution could essentially be tuned by adjusting the operating temperature. The scope of this study was limited to isothermal conditions and attaching polymer chains to glass beads.
==== X-ray passport ==== Since 2002, an x-ray pass is a document in which the examining physician or dentist must enter information about the x-ray examinations performed on the patient. The main aim was to avoid unnecessary repeat examinations. According to the new Radiation Protection Ordinance (StrlSchV), practices and clinics are no longer obliged to offer their patients X-ray passports and to enter examinations in them. The Radiation Protection Ordinance came into force on December 31, 2018, together with the Radiation Protection Act (StrlSchG) passed in 2017, replacing the previous Radiation Protection Ordinance and the X-ray Ordinance. The Federal Office for Radiation Protection (BfS) continues to advise patients to keep records of their own radiation diagnostic examinations. On its website, the BfS provides a downloadable document that can be used for personal documentation.
== History == One of the first scientific reports is the colloidal gold particles synthesized by Michael Faraday as early as 1857. By the early 1940's, precipitated and fumed silica nanoparticles were being manufactured and sold in USA and Germany as substitutes for ultrafine carbon black for rubber reinforcements.
Sources: en.wikipedia.org
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.
Lyophilized powder is usually kept frozen, desiccated, and protected from light. Reconstituted solutions are often divided into aliquots and stored at very low temperature to limit freeze-thaw cycles. Specific conditions should follow the supplier's certificate of analysis and the assay requirements.
Much of the evidence comes from animal models and cell-based assays rather than large human trials. Small sample sizes, short follow-up, and differences in dosing or route make comparisons difficult. Questions about long-term effects and human relevance remain open.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.